Applying Platelet Rich Plasma (PRP) Gel to Acute Deep Partial Thickness Thermal Injuries
- Conditions
- Acute Deep Partial Thickness Thermal Burns
- Interventions
- Device: Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)
- First Posted Date
- 2014-06-23
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Arteriocyte, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT02169362
- Locations
- 🇺🇸
University of California, Davis Medica Center, Sacramento, California, United States
🇺🇸Jaycee Burn Center at University of North Carolina, Chapel Hill, North Carolina, United States
🇺🇸Lehigh Valley Health Network, Allentown, Pennsylvania, United States
Registry Trial of the Effectiveness of Platelet Rich Plasma for Chronic Non-Healing Wounds
- Conditions
- Diabetic Foot UlcersPressure UlcersVenous Ulcers
- Interventions
- Device: Autologous PRP InjectionsDevice: Autologous PRP GelProcedure: Standard Wound CareDevice: Autologous PRP Gel plus PRP Injections
- First Posted Date
- 2014-02-26
- Last Posted Date
- 2018-01-16
- Lead Sponsor
- Arteriocyte, Inc.
- Target Recruit Count
- 1500
- Registration Number
- NCT02071979
- Locations
- 🇺🇸
Total Foot Care, Cleveland, Ohio, United States
🇺🇸Heritage Valley Health System, Beaver, Pennsylvania, United States
🇺🇸Sunnyside Foot and Ankle, Idaho Falls, Idaho, United States
Using Autologous Platelet Rich Plasma (PRP) Gel to Treat Deep 2nd and 3rd Degree Burns
- Conditions
- Acute Burns
- Interventions
- Device: Magellan®Other: Placebo Saline Gel and Usual and Customary Standard of Care
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2018-01-09
- Lead Sponsor
- Arteriocyte, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT01843686
- Locations
- 🇺🇸
Medstar Health Research Institute, Washington, District of Columbia, United States
🇺🇸University of California, Davis, Division of Burn Surgery, Sacramento, California, United States
🇺🇸University of Utah Hospital, Salt Lake City, Utah, United States
Phase I, Arteriocyte Magellan MAR01 Therapy - Compartment Syndrome and Battlefield Trauma
- Conditions
- Compartment Syndrome
- Interventions
- Device: Magellan®
- First Posted Date
- 2013-04-23
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Arteriocyte, Inc.
- Target Recruit Count
- 5
- Registration Number
- NCT01837264
- Locations
- 🇺🇸
Advocate Christ Medical Center, Oak Lawn, Illinois, United States
Safety Study of Bone Marrow Cell Concentrate Prepared Using the Magellan System to Treat Critical Limb Ischemia (CLI)
- Conditions
- Critical Limb Ischemia (CLI)Peripheral Vascular Disease (PVD)
- Interventions
- Device: Magellan®
- First Posted Date
- 2011-07-01
- Last Posted Date
- 2017-01-24
- Lead Sponsor
- Arteriocyte, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT01386216
- Locations
- 🇺🇸
The Ohio State University Medical Center, Columbus, Ohio, United States